Journal article icon

Journal article

A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI

Abstract:

Background Ischemia-reperfusion injury remains a major clinical problem in patients with ST-elevation myocardial infarction (STEMI), leading to myocardial damage despite early reperfusion by primary percutaneous coronary intervention (PPCI). There are no effective therapies to limit ischemia-reperfusion injury, which is caused by multiple pathways activated by rapid tissue reoxygenation and the generation of reactive oxygen species (ROS). FDY-5301 contains sodium iodide, a ubiquitous inorgan...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


Expand authors...
More from this funder
Grant:
CH/16/1/32013
SP/17/16/33519
Publisher:
Elsevier Publisher's website
Journal:
International Journal of Cardiology Journal website
Volume:
347
Pages:
1-7
Publication date:
2021-11-12
Acceptance date:
2021-11-07
DOI:
EISSN:
1874-1754
ISSN:
0167-5273
Pmid:
34774885

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP